#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13924	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2050	673.7	0	.	n	.	0	C451T	SNP	451	451	C	647	647	T	861	T	783	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13924	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2050	673.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1380	1380	C	825	C,T	740,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25786	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3558	722.8	0	.	n	.	0	T695C	SNP	695	695	T	1067	1067	C	829	C	747	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25786	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3558	722.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2343	2343	C	825	C,T	727,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25786	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3558	722.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2417	2417	A	818	A	747	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25786	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3558	722.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2969	2969	C	814	C	734	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	1924	folP	855	855	100.0	folP.l6.c17.ctg.1	1262	150.4	1	SNP	p	R229S	1	.	.	685	687	AGC	899	901	AGC	221;222;222	A;G;C	205;206;203	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4908	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3351	146.1	1	SNP	p	S91F	1	.	.	271	273	TTC	583	585	TTC	143;145;146	T;T;C	129;131;131	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4908	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3351	146.1	1	SNP	p	G95N	0	.	.	283	285	GGC	595	597	GGC	142;142;143	G;G;C	127;125;126	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4908	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3351	146.1	1	SNP	p	D95G	1	.	.	283	285	GGC	595	597	GGC	142;142;143	G;G;C	127;125;126	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1576	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1362	115.5	1	SNP	p	G45D	0	.	.	133	135	GGC	523	525	GGC	197;193;196	G;G;C	180;173;177	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	660	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	881	74.1	0	.	n	.	0	A197.	DEL	197	197	A	462	462	A	149	A	141	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4840	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2948	163.7	1	SNP	p	D86N	0	.	.	256	258	GAC	567	569	GAC	228;227;229	G;A;C	204;203;207	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4840	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2948	163.7	1	SNP	p	R87W	0	.	.	259	261	CGT	570	572	CGT	230;228;226	C;G;T	207;204;202	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4840	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2948	163.7	1	SNP	p	R87I	0	.	.	259	261	CGT	570	572	CGT	230;228;226	C;G;T	207;204;202	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4840	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2948	163.7	1	SNP	p	S87R	1	.	.	259	261	CGT	570	572	CGT	230;228;226	C;G;T	207;204;202	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4840	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2948	163.7	1	SNP	p	S88P	0	.	.	262	264	TCC	573	575	TCC	227;226;226	T;C;C	203;204;205	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4158	parE	1986	1986	100.0	parE.l15.c30.ctg.1	2681	154.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1520	1522	GGC	211;203;205	G;G;C	185;178;177	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	3718	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2476	149.6	1	SNP	p	A311V	0	.	.	931	933	GCC	1353	1355	GCC	209;210;212	G;C;C	189;188;192	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3718	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2476	149.6	1	SNP	p	I312M	1	.	.	934	936	ATG	1356	1358	ATG	216;216;213	A;T,C;G	194;192,1;193	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3718	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2476	149.6	1	SNP	p	T316P	0	.	.	946	948	ACC	1368	1370	ACC	214;212;212	A;C;C	192;191;191	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3718	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2476	149.6	1	SNP	p	V316T	1	.	.	946	948	ACC	1368	1370	ACC	214;212;212	A;C;C	192;191;191	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3718	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2476	149.6	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1869	1871	ACC	209;209;208	A;C;C	176;181;180	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3718	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2476	149.6	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1923	1925	GCG	209;205;206	G;C;G	189;183;187	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3718	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2476	149.6	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1923	1925	GCG	209;205;206	G;C;G	189;183;187	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3718	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2476	149.6	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2046	2048	GGT	180;181;179	G;G;T,C	155;156;153,1	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3718	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2476	149.6	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2055	2057	AGC	177;174;172	A;G;C	152;152;150	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3718	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2476	149.6	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2073	2075	CCG	147;147;149	C,G;C;G,A	109,6;112;109,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5192	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3199	161.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1669	1671	CCG	203;203;201	C,T;C;G	175,1;177;176	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1838	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1560	116.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	438	438	C	134	C	115	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	262	porB1a	984	296	91.0	porB1a.l15.c17.ctg.2	369	24.7	0	.	p	.	0	H217N	NONSYN	649	651	CAT	98	100	AAT	14;14;14	A;A;T	14;14;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	262	porB1a	984	296	91.0	porB1a.l15.c17.ctg.2	369	24.7	0	.	p	.	0	D218N	NONSYN	652	654	GAT	101	103	AAT	13;13;13	A;A;T	13;13;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	262	porB1a	984	296	91.0	porB1a.l15.c17.ctg.2	369	24.7	0	.	p	.	0	V226A	NONSYN	676	678	GTA	125	127	GCA	14;14;14	G;C;A	14;14;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	262	porB1a	984	296	91.0	porB1a.l15.c17.ctg.2	369	24.7	0	.	p	.	0	.	MULTIPLE	700	702	ACT	148	150	GTA	14;14;13	G;T;A	14;14;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	262	porB1a	984	296	91.0	porB1a.l15.c17.ctg.2	369	24.7	0	.	p	.	0	N237fs	FSHIFT	709	709	A	157	157	A	15	A	15	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2754	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1558	175.8	0	.	p	.	0	G210R	NONSYN	628	630	GGA	895	897	AGA	206;206;208	A;G;A	187;185;187	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2754	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1558	175.8	0	.	p	.	0	S217G	NONSYN	649	651	AGT	916	918	GGT	203;196;198	G;GTTT,GTTTT;T	189;179,1;181	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2754	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1558	175.8	1	SNP	p	G120K	1	.	.	358	360	AAG	625	627	AAG	256;256;259	A;A;G	232;230;228	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2754	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1558	175.8	1	SNP	p	A121N	1	.	.	361	363	AAC	628	630	AAC	258;257;256	A;A;C	228;229;224	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2754	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1558	175.8	1	SNP	p	N121D	0	.	.	361	363	AAC	628	630	AAC	258;257;256	A;A;C	228;229;224	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10572	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	4724	223.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1152	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1011	113.5	1	SNP	p	V57M	1	.	.	169	171	ATG	513	515	ATG	218;213;211	A;T;G,A	199;195;191,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
